Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer

X
Trial Profile

Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer; Ovarian cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Sep 2022 Pooled analysis assessing HRD data detected by panel sequencing obtained as part of routine clinical care published in the Clinical Cancer Research.
    • 11 Feb 2022 Results (n=17) published in the Clinical Cancer Research
    • 21 May 2021 Results assessing correlative analysis of Sig3 as predictor of response by using data from this study presented at the 112th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top